{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010958","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.203354+00:00","generated_at":"2026-05-31T12:14:05.393866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KALA BIO reports Q2 net loss of $9.6M, cash $54.2M; Phase 2b data due Q1 2025","bullets":["Net loss of $9.6M ($3.16 per share) for Q2 2024 vs. $10.4M ($4.36 per share) a year ago.","Cash and equivalents $54.2M at June 30, 2024; with CIRM award, runway expected into Q4 2025.","Closed $12.5M private placement led by SR One; net proceeds of $12.3M.","Topline results from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025.","R&D expenses rose to $5.3M from $4.3M on higher KPI-012 development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010958","json":"https://secwatch.observer/filing/0001558370-24-010958.json","markdown":"https://secwatch.observer/filing/0001558370-24-010958.md","text":"https://secwatch.observer/filing/0001558370-24-010958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024010958/0001558370-24-010958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024010958/kala-20240806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:14:05.393866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}